Grifols Therapeutics
CompanySpainFounded 1909
Grifols Therapeutics develops one asset, in phase 3 (Alpha-1 MP in pulmonary emphysema in Alpha-1 PI deficiency). Mostly protein or enzyme acting on proteostasis and SERPINA1; based in Spain, founded in 1909.
- 1
- Asset
- Furthest stage
- Phase 3
- 1
- Trial
- 0
- Signals
Pipeline
1Human alpha-1 proteinase inhibitor augmentation therapy inhibiting neutrophil elastase to protect lung tissue.
Phase 3, Protein or enzyme, Proteostasis, SERPINA1, pulmonary emphysema in Alpha-1 PI deficiency
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials1
- Similar companies6